Maiko Miyagawa1, Shin-Ya Nishio1, Yuika Sakurai2, Mitsuru Hattori3, Keita Tsukada3, Hideaki Moteki1, Hiromi Kojima2, Shin-Ichi Usami4. 1. Department of Otorhinolaryngology, Shinshu University School of Medicine Matsumoto, Japan Department of Hearing Implant Sciences, Shinshu University School of Medicine, Matsumoto, Japan. 2. Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan. 3. Department of Otorhinolaryngology, Shinshu University School of Medicine Matsumoto, Japan. 4. Department of Otorhinolaryngology, Shinshu University School of Medicine Matsumoto, Japan Department of Hearing Implant Sciences, Shinshu University School of Medicine, Matsumoto, Japan usami@shinshu-u.ac.jp.
Abstract
OBJECTIVES: To clarify the frequency of TMPRSS3 mutations in the hearing loss population, genetic analysis was performed, and detailed clinical characteristics were collected. Optical intervention for patients with TMPRSS3 mutations was also discussed. METHODS: Massively parallel DNA sequencing (MPS) was applied for the target exon-sequencing of 63 deafness genes in a population of 1120 Japanese hearing loss patients. RESULTS: Hearing loss in 5 patients was found to be caused by compound heterozygous TMPRSS3 mutations, and their detailed clinical features were collected and analyzed. Typically, all of the patients showed ski slope type audiograms and progressive hearing loss. Three of the 5 patients received electric acoustic stimulation (EAS), which showed good results. Further, the onset age was found to vary, and there were some correlations between genotype and phenotype (onset age). CONCLUSIONS: MPS is a powerful tool for the identification of rare causative deafness genes, such as TMPRSS3. The present clinical characteristics not only confirmed the findings from previous studies but also provided clinical evidence that EAS is beneficial for patients possessing TMPRSS3 mutations.
OBJECTIVES: To clarify the frequency of TMPRSS3 mutations in the hearing loss population, genetic analysis was performed, and detailed clinical characteristics were collected. Optical intervention for patients with TMPRSS3 mutations was also discussed. METHODS: Massively parallel DNA sequencing (MPS) was applied for the target exon-sequencing of 63 deafness genes in a population of 1120 Japanese hearing losspatients. RESULTS:Hearing loss in 5 patients was found to be caused by compound heterozygous TMPRSS3 mutations, and their detailed clinical features were collected and analyzed. Typically, all of the patients showed ski slope type audiograms and progressive hearing loss. Three of the 5 patients received electric acoustic stimulation (EAS), which showed good results. Further, the onset age was found to vary, and there were some correlations between genotype and phenotype (onset age). CONCLUSIONS:MPS is a powerful tool for the identification of rare causative deafness genes, such as TMPRSS3. The present clinical characteristics not only confirmed the findings from previous studies but also provided clinical evidence that EAS is beneficial for patients possessing TMPRSS3 mutations.
Authors: Jourdan T Holder; William Morrel; Alejandro Rivas; Robert F Labadie; René H Gifford Journal: Otol Neurotol Date: 2021-03-01 Impact factor: 2.311
Authors: Thomas Parzefall; Alexandra Frohne; Martin Koenighofer; Andreas Kirchnawy; Berthold Streubel; Christian Schoefer; Wolfgang Gstoettner; Klemens Frei; Trevor Lucas Journal: Wien Klin Wochenschr Date: 2017-07-21 Impact factor: 1.704
Authors: A Eliot Shearer; Viral D Tejani; Carolyn J Brown; Paul J Abbas; Marlan R Hansen; Bruce J Gantz; Richard J H Smith Journal: Sci Rep Date: 2018-09-21 Impact factor: 4.379